It’s unclear why we were selected for a social media audit. As a company dedicated to developing life-changing cell and gene therapies for patients with limited treatment options, our work is both time-sensitive and highly specialised. Disruptions to our day-to-day operations, particularly in our laboratories, can directly delay the progress of vital new treatments. We’re […]
Apr 11, 2025
Why were we targeted, and why is this concerning?
It’s unclear why we were selected for a social media audit. As a company dedicated to developing life-changing cell and gene therapies for patients with limited treatment options, our work is both time-sensitive and highly specialised. Disruptions to our day-to-day operations, particularly in our laboratories, can directly delay the progress of vital new treatments.
We’re sharing this to remain transparent with our clients, employees, and partners, and to raise awareness of the broader harm such campaigns can cause, not just to us, but to the patient communities we serve.
We remain focused on our mission, supporting clients and collaborators while upholding the high standards of professionalism, transparency, and integrity that define who we are.
If you have any questions about this matter, please contact us at [email protected]
Latest News

eXmoor Pharma and Signadori Bio launch partnership to develop next-generation monocyte-based cell therapy for solid tumours

Scaling Gene Therapy Production: From Bench to Clinic

eXmoor Pharma and KU Leuven announce strategic partnership to accelerate cell and gene therapy innovation through new venture
Let’s Accelerate Your Therapy Together
Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.